Motif (MTFB) Now Covered by Analysts at Northland Securities

Northland Securities initiated coverage on shares of Motif (NASDAQ:MTFB) in a research report report published on Monday, The Fly reports. The brokerage issued an outperform rating on the stock.

Several other analysts have also recently weighed in on the stock. Gabelli reaffirmed a hold rating on shares of Motif in a report on Thursday, March 29th. ValuEngine raised shares of Motif from a strong sell rating to a sell rating in a report on Friday, February 2nd. WBB Securities assumed coverage on shares of Motif in a report on Friday, December 29th. They issued a sell rating and a $7.00 target price on the stock. Finally, Seaport Global Securities reaffirmed a buy rating on shares of Motif in a report on Friday, December 22nd. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company. The stock has an average rating of Hold and an average price target of $21.33.

How to Become a New Pot Stock Millionaire

Shares of NASDAQ:MTFB opened at $9.95 on Monday. Motif has a fifty-two week low of $6.84 and a fifty-two week high of $13.75. The company has a current ratio of 0.96, a quick ratio of 0.96 and a debt-to-equity ratio of -1.58.

ILLEGAL ACTIVITY NOTICE: This piece of content was published by Week Herald and is the sole property of of Week Herald. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The correct version of this piece of content can be read at https://weekherald.com/2018/04/17/motif-mtfb-now-covered-by-analysts-at-northland-securities.html.

Motif Company Profile

Motif Bio plc, a clinical stage biopharmaceutical company, develops and commercializes pharmaceutical formulations in the United States. The company develops novel antibiotics for the treatment of serious and life-threatening infections caused by multi-drug resistant bacteria. Its lead product candidate is Iclaprim, a novel antibiotic that is in Phase III clinical trials to treat bacterial infections, such as acute bacterial skin and skin structure infections, and hospital acquired bacterial pneumonia caused by methicillin-resistant staphylococcus aureus.

The Fly

Analyst Recommendations for Motif (NASDAQ:MTFB)

Receive News & Ratings for Motif Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motif and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply